The cited record supports the material proposition.
The US Justice Department said Purdue Pharma pleaded guilty in November 2020 to three federal felonies tied to its opioid marketing.
- About
- Purdue Pharma L.P.
- Claim made by
- US Department of Justice, regulator statement
- Published
- 24 November 2020
- Evidence score
- 87 How it was scored
- Last reviewed
- 25 October 2026
Why this label
The department's release says Purdue pleaded guilty in federal court in Newark, New JerseyS2. The counts were one dual-object conspiracy to defraud the United States and to violate the Food, Drug, and Cosmetic Act, and two counts of conspiracy to violate the Anti-Kickback StatuteS2. The agreed terms included a criminal fine of US$3.544 billion and US$2 billion in criminal forfeiture, and a civil claim of US$2.8 billion in the bankruptcyS2. The release does not report sentencing, and the sentencing record was not read here. The plea itself is the company's admission of guilt on those counts.
Current procedural position
Guilty plea entered on 24 November 2020 in the US District Court for the District of New JerseyS2. Sentencing record not read as of October 2026.
Record supporting the assessment
one count of dual-object conspiracy to defraud the United States and to violate the Food, Drug, and Cosmetic Act
two counts of conspiracy to violate the Federal Anti-Kickback Statute
Conflicting or limiting record
No record located that conflicts with this assessment.
Evidence score: 87 of 100
The score grades how well the record establishes this assessment. It is not a score of Purdue Pharma L.P.. Score = source authority + directness + corroboration + procedural accuracy + currency + reproducibility.
| Component | Points | Max | Reason |
|---|---|---|---|
| Source authorityIs the source competent to establish the proposition? | 27 | 30 | A DOJ release is competent to report the plea it obtained. |
| DirectnessDoes the source state the proposition or only discuss adjacent facts? | 20 | 20 | The release names each count. |
| CorroborationDo independent records support the same material point? | 10 | 15 | The bankruptcy releases are consistent, but no court plea record was read. |
| Procedural accuracyDoes the record settle the procedural state the claim describes? | 12 | 15 | The plea is entered. Sentencing was not confirmed. |
| CurrencyHas the record been checked against later developments? | 8 | 10 | Checked against the 2025 and 2026 bankruptcy releases. |
| ReproducibilityCan a reader locate the passage and repeat the assessment? | 10 | 10 | The release is public on justice.gov. |
| Total | 87 | 100 |
Timeline
- Purdue pleads guilty in NewarkS2
Related cases
- United States v. Purdue Pharma L.P.US District Court for the District of New Jersey. Criminal. Not confirmed in the records read.Stage: Guilty plea entered on 24 November 2020. Sentencing record not read.
- Guilty plea to three felony conspiracy countsS2
Revision history
- Assessment first published with label Supported.
Have a record that changes this assessment? See corrections and responses.
Sources
- S2Tier A Opioid Manufacturer Purdue Pharma Pleads Guilty to Fraud and Kickback ConspiraciesUS Department of Justice. Government press release. 24 November 2020.Reports the 2020 plea counts and agreed amounts. It does not report sentencing.Link working, checked 25 October 2026
Other claims about Purdue Pharma L.P.
- Contradicted88Purdue's original OxyContin label said that delayed absorption from OxyContin tablets was believed to reduce the drug's abuse liability.Official report, 31 July 20074 records citedProduct claims
- Outdated94Purdue said in May 2023 that the Second Circuit had upheld its plan of reorganization, which included releases of opioid claims against members of the Sackler family.Company statement, 30 May 20232 records citedCorporate status
- Supported83Purdue said in November 2025 that the bankruptcy court would confirm its new plan, which provides about US$7.4 billion in cash to creditors.Company statement, 14 November 20254 records citedCorporate status